Immediate Impact
1 by Nobel laureates 55 standout
Citing Papers
Endometriosis Typology and Ovarian Cancer Risk
2024 Standout
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
2023 Standout
Works of Amelia Zelnak being referenced
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
2022
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Amelia Zelnak | 514 | 376 | 303 | 310 | 44 | 971 | |
| Cansu Karakaş | 585 | 354 | 207 | 422 | 36 | 978 | |
| André T. Brunetto | 438 | 255 | 174 | 510 | 56 | 1.2k | |
| J Gioanni | 354 | 178 | 275 | 377 | 36 | 887 | |
| Urszula M. Polanska | 421 | 219 | 207 | 480 | 29 | 862 | |
| Katherine Tkaczuk | 387 | 199 | 255 | 309 | 33 | 941 | |
| Mariam Jamal‐Hanjani | 459 | 375 | 403 | 427 | 38 | 1.1k | |
| Kazuharu Kai | 560 | 138 | 430 | 472 | 38 | 1.1k | |
| Frank C. Cackowski | 551 | 309 | 299 | 542 | 41 | 1.1k | |
| Steven Gendreau | 414 | 480 | 348 | 547 | 26 | 1.1k | |
| M. Beeram | 447 | 301 | 168 | 396 | 48 | 841 |
All Works
Loading papers...